<span item_type="fundamental" item_id="4f8f62363a84cdc2997677de3afa629b" counter_id="ST/US/SLXNW" env="prod"></span><span item_type="announcement" item_id="548602886609638401" env="prod"></span><p>EPS: As of FY2025 Q2, the actual value is USD -4.32.</p><p>EBIT: As of FY2025 Q2, the actual value is USD -2.5 M.</p><p></p><h3>Cash Position</h3><p>Cash and cash equivalents were $3.5 million as of June 30, 2025, compared to $1.2 million as of December 31, 2024, reflecting proceeds from financing activities completed in early 2025, partially offset by ongoing operational expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325002784/exhibit_99-1.htm"></span></p><h3>Operating Expenses</h3><p>Total operating expenses for the three-month period ended June 30, 2025 were $2.3 million, compared to $1.4 million for the same period in 2024, an increase of 64.3%. Research and development expenses increased to $1.0 million, up from $0.8 million in 2024, primarily due to increased payroll and payroll-related expenses. General and administrative expenses rose to $1.3 million from $0.6 million, mainly due to increased payroll expenses and professional services costs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325002784/exhibit_99-1.htm"></span></p><h3>Financial Expenses</h3><p>Financial expenses, net for the three-month period ended June 30, 2025 were $0.2 million, compared to $0.1 million for the same period in 2024, an increase of 100.0%, primarily due to an increase in revaluation expenses of financial instruments.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325002784/exhibit_99-1.htm"></span></p><h3>Net Loss</h3><p>Net loss for the three-month period ended June 30, 2025 was $2.5 million, compared to $1.5 million for the same period in 2024, an increase of 66.7%. For the six months ended June 30, 2025, net loss was $4.2 million compared to $2.9 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325002784/exhibit_99-1.htm"></span></p><h3>Outlook / Guidance</h3><p>Silexion plans to initiate Phase <sup>2</sup>⁄<sub>3</sub> clinical trials for SIL204 in the first half of 2026, focusing initially on locally advanced pancreatic cancer. The company is conducting toxicology studies to initiate the clinical trial, with regulatory submissions planned for the fourth quarter of 2025 to the Israel Ministry of Health and the first quarter of 2026 to the European Union.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2022416/000117891325002784/exhibit_99-1.htm"></span></p>

SILEXION THERAPEUTICS CORP C/WTS EXP 15/08/2029 (TO PUR COM) | 8-K: FY2025 Q2 EPS: USD -4.32